| Identification | Back Directory | [Name]
DEHYDROXYMETHYLEPOXYQUINOMICIN | [CAS]
287194-40-5 | [Synonyms]
DHMEQ
DHM2EQ
DEHYDROXYMETHYLEPOXYQUINOMICIN
Dehydroxymethylepoxyquinomicin (DHMEQ)
(-)-DHMEQ?(dehydroxymethylepoxyquinomicin)
2-hydroxy-N-[(1S,2S,6S)-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]benzaMide
Benzamide, 2-hydroxy-N-[(1S,2S,6S)-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]- | [Molecular Formula]
C13H11NO5 | [MDL Number]
MFCD04974863 | [MOL File]
287194-40-5.mol | [Molecular Weight]
261.23 |
| Chemical Properties | Back Directory | [Melting point ]
187 °C | [Boiling point ]
617.2±55.0 °C(Predicted) | [density ]
1.58±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 32 mg/mL (122.50 mM) | [form ]
Solid | [pka]
8.43±0.30(Predicted) | [color ]
Off-white to gray |
| Hazard Information | Back Directory | [Uses]
(-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity[1][2][3]. | [in vivo]
(-)-DHMEQ (4 mg/kg or 12 mg/kg; intraperitoneal injection; on day 0 and 3 times a week; for one month; SCID mice) treatment shows a significant increase in the survival rate in mice[2]. | Animal Model: | Male C.B17-scid/scid (5 weeks old) mice injected with MT-2 cells[2] | | Dosage: | 4 mg/kg or 12 mg/kg | | Administration: | Intraperitoneal injection; on day 0 and 3 times a week; for one month | | Result: | Showed a significant increase in the survival rate in mice.
|
| [IC 50]
RelA; RelB | [References]
[1] Yinzhi Lin, et al. Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review. DOI:10.3390/ijms19030729
[2] Mariko Watanabe, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005 Oct 1;106(7):2462-71. DOI:10.1182/blood-2004-09-3646
[3] Quach HT, et al. Eudesmane-Type Sesquiterpene Lactones Inhibit Nuclear Translocation of the Nuclear Factor κB Subunit RelB in Response to a Lymphotoxin β Stimulation. Biol Pharm Bull. 2017;40(10):1669-1677. DOI:10.1248/bpb.b17-00170 |
|
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|